SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 63 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,789,205 | +1567.5% | 192,094 | +2325.4% | 0.02% | +2000.0% |
Q1 2023 | $167,270 | -83.4% | 7,920 | -86.3% | 0.00% | -87.5% |
Q1 2022 | $1,005,000 | +22.1% | 57,804 | +53.7% | 0.01% | 0.0% |
Q4 2021 | $823,000 | +162.9% | 37,598 | +129.4% | 0.01% | +100.0% |
Q3 2021 | $313,000 | -13.8% | 16,393 | -22.6% | 0.00% | 0.0% |
Q2 2021 | $363,000 | -3.2% | 21,166 | +26.4% | 0.00% | -20.0% |
Q1 2021 | $375,000 | -51.0% | 16,751 | -51.4% | 0.01% | -54.5% |
Q4 2020 | $766,000 | +571.9% | 34,447 | +347.4% | 0.01% | +450.0% |
Q3 2020 | $114,000 | -50.2% | 7,700 | -50.2% | 0.00% | -50.0% |
Q2 2020 | $229,000 | +1247.1% | 15,461 | +621.1% | 0.00% | +300.0% |
Q3 2018 | $17,000 | +6.2% | 2,144 | +78.7% | 0.00% | 0.0% |
Q1 2017 | $16,000 | -15.8% | 1,200 | -55.0% | 0.00% | -50.0% |
Q4 2016 | $19,000 | – | 2,666 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |